Battelle Secures $44M EPA Contract for Endocrine Disruptor Research
Event summary
- Battelle wins one of three blanket purchase agreements from the EPA to evaluate endocrine-disrupting chemicals, with a total ceiling value of $44 million over five years.
- The contract focuses on identifying potential endocrine-disrupting chemicals and evaluating hazards, exposures, and risks to human health and the environment.
- Battelle's research will include studying substances like pesticides, pharmaceuticals, phthalates, bisphenol A, parabens, and antimicrobials including triclosan.
- The company has been researching endocrine disruption since 2001, with the preceding contract completed in 2024.
The big picture
Battelle's new EPA contract underscores the growing emphasis on understanding and mitigating the effects of endocrine-disrupting chemicals. This research is critical for public health and environmental safety, positioning Battelle as a key player in regulatory compliance and advanced scientific methodologies. The $44 million ceiling value over five years highlights the scale of investment in this area.
What we're watching
- Regulatory Compliance
- How the EPA's focus on endocrine-disrupting chemicals will shape future regulatory frameworks and industry standards.
- Research Efficiency
- Whether Battelle can sustain its role in advancing in vitro methods and reducing reliance on animal testing for chemical evaluations.
- Market Dynamics
- The pace at which other companies may enter the endocrine-disruptor research space, given the significant contract value and long-term research potential.